Sun Pharmaceutical Medicare Ltd. – FDA 483, Sep 19, 2023

Sun Pharmaceutical Medicare Ltd., located in Halol, Gujarat, India, underwent an FDA inspection from September 18 to 19, 2023. The inspection revealed significant violations in the company's aseptic processing practices, crucial for maintaining the sterility of drug products. The primary issues included inadequate procedures to prevent microbiological contamination and insufficient validation of sterilization processes. Specifically, operators were observed performing aseptic connections without proper sanitization and using incorrect techniques, such as handling sterile components without sanitizing hands beforehand.

The inspection also highlighted deficiencies in environmental monitoring systems. There were numerous rejections of product batches due to excursions in environmental and personnel monitoring parameters, indicating lapses in maintaining controlled conditions in aseptic processing areas. Furthermore, airflow visualization studies revealed issues with unidirectional airflow and turbulent conditions, potentially compromising product sterility.

The FDA's observations necessitate immediate corrective actions from Sun Pharmaceutical Medicare Ltd. The company is required to establish and rigorously follow comprehensive procedures for aseptic processing, ensure proper training and sanitization practices for operators, and enhance their environmental monitoring systems to prevent future violations. Compliance with these requirements is essential to align with FDA regulations and ensure the safety and efficacy of their sterile drug products.